Sanofi (EPA:SAN)
81.45
-0.58 (-0.71%)
Apr 21, 2026, 2:50 PM CET
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
€624,162
Profits / Employee
€104,388
Market Cap
99.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| emeis Société anonyme | 83,500 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,694 |
| Ramsay Générale de Santé | 40,000 |
| bioMérieux | 15,226 |
| Sartorius Stedim Biotech | 10,265 |
| Virbac | 6,365 |
Sanofi News
- 2 days ago - Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study - Nasdaq
- 3 days ago - Sanofi (SNY) Vaccine Study Shows Lower Side Effects Compared to Competitor - GuruFocus
- 3 days ago - France's 2026 Market Story Could Stay Centered On Luxury, Pharma And Banks - Benzinga
- 3 days ago - Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says - Benzinga
- 4 days ago - AMUNDI's Strategic Acquisition of Sanofi SA Shares - GuruFocus
- 4 days ago - Sanofi (SNY) Benefits from Vir Biotechnology's Collaboration with Astellas - GuruFocus
- 8 days ago - Sanofi (SNY) Gains EU Approval for Dupixent in Young Patients with CSU - GuruFocus
- 8 days ago - Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU - Nasdaq